In June 2021, Beijing Zhongda Wecomput Technology Co., Ltd. (hereinafter referred to as “Wecomput”) successfully secured a multi-million dollar investment from Sequoia Capital. This funding will primarily be used for the integration, optimization, and technological upgrade of new drug development platform products such as WeMol, further enhancing Wecomput’s leading position in the domestic biopharmaceutical computational services market, promoting strategic cooperation with top pharmaceutical companies, expanding business areas, and strengthening the technical and management teams.
Wecomput is one of the earliest professional computational service providers in the biopharmaceutical field in China. Its fixed clientele includes hundreds of universities, hospitals, pharmaceutical companies, and drug research institutions both domestically and internationally, enjoying high industry recognition and reputation. WeMol, an independently developed new drug development platform by Wecomput, supports the discovery, design, and optimization of new drugs in fields such as macromolecular biologics, small molecule chemical drugs, mRNA, biomaterials, and traditional Chinese medicine natural products. WeMol integrates a series of proprietary core algorithms, surpassing or rivaling international mainstream commercial software in terms of speed, accuracy, and storage efficiency.
China’s innovative drug sector is in a period of rapid development, and biopharmaceutical information computing holds significant potential in this field. High-performance computing, in particular, can serve as a new engine for innovative drug development, injecting strong momentum into scientific research. This successful financing is a recognition of Wecomput’s promising development prospects by the capital market. Wecomput will take this opportunity to further improve its product line represented by WeMol, strengthen the application of emerging information technologies such as AI and CADD in new drug development, and enhance its reputation and influence in the industry.
“Guided by information, rooted in credibility, propelled by belief, and fortified by confidence.” With the support of capital, Wecomput will provide better products and services to domestic drug researchers, jointly addressing future challenges.
About Sequoia Capital
Sequoia Capital is a renowned multinational venture capital firm, known as the “Entrepreneurs Behind the Entrepreneurs.” It focuses on identifying and discovering investment opportunities in four directions: technology/media, healthcare, consumer goods/services, and industrial technology. Over the past 16 years, Sequoia Capital China Fund has invested in nearly 600 companies with distinct technological characteristics, innovative business models, and high growth potential. Sequoia Capital is known for its keen eye in identifying long-term value in companies, having successfully invested in many well-known enterprises in China, including JD.com, Alibaba, Ant Financial, ByteDance, Vipshop, Pinduoduo, WuXi AppTec, and Zai Lab.